Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease|
|Citation:||Expert Opinion on Pharmacotherapy, 2009; 10(17):2897-2904|
|Publisher:||Ashley Publications Ltd.|
|P. Rolan, M.R. Hutchinson & K.W. Johnson|
|Abstract:||Ibudilast is a relatively nonselective phosphodiesterase inhibitor which has been marketed for almost 20 years in Japan for treating asthma. More recently it has been found to have anti-inflammatory activity in both the peripheral immune system and in the CNS via glial cell attenuation. This CNS-directed anti-inflammatory activity is of potential use in the treatment of multiple sclerosis, neuropathic pain, and in the improved efficacy and safety of opioids by decreasing opioid tolerance, withdrawal and reinforcement. Its suitable pharmacokinetics and generally good tolerability make it a promising potential treatment for these conditions.|
|Keywords:||glia; ibudilast; multiple sclerosis; neuropathic pain; priming|
|Description:||© 2009 Informa UK Ltd|
|Appears in Collections:||Pharmacology publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.